HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maki, D. G. Articles by Myerowitz, P. D. Search for Related Content PubMed PubMed Citation Articles by Maki, D. G. Articles by Myerowitz, P. D.

The Journal of Thoracic and Cardiovascular Surgery, Vol 104, 1423-1434, Copyright © 1992 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial

DG Maki, MJ Bohn, SM Stolz, GM Kroncke, CW Acher and PD Myerowitz
Department of Medicine, University of Wisconsin Medical School, Madison.

Three-hundred twenty-one adults undergoing cardiac or major vascular operations were randomized to receive intravenous cefazolin, cefamandole, or vancomycin for prophylaxis against surgical infection in a double-blind trial. All three regimens provided therapeutic blood levels throughout operation in patients studied undergoing cardiopulmonary bypass. The prevalence of surgical wound infection was lowest with vancomycin (4 infections [3.7%] versus 14 [12.3%] and 13 [11.5%] in the cefazolin and cefamandole groups, respectively; p = 0.05); there were no thoracic wound infections in cardiac operations in the vancomycin group (p = 0.04). The mean duration of postoperative hospitalization was lowest in the vancomycin group (10.1 days; p < 0.01) and highest in the cefazolin group (12.9 days). Prophylaxis with vancomycin or cefamandole, compared with cefazolin, did not prevent nosocomial cutaneous colonization by methicillin-resistant coagulase- negative staphylococci; colonization or infection with vancomycin- resistant staphylococci or enterococci was not detected. Adverse effects attributable to the prophylactic regimen were infrequent in all three groups. Eight patients given vancomycin became hypotensive during administration of a dose, despite infusion during a 1-hour period; however, slowing the rate of administration and pretreating with diphenhydramine allowed vancomycin to be resumed and prophylaxis completed uneventfully in five of the patients. We conclude that administration of vancomycin (approximately 15 mg/kg), immediately preoperatively, provides therapeutic blood levels for surgical prophylaxis throughout most cardiac and vascular operations, resulting in protection against postoperative infection superior to that obtained with cefazolin or cefamandole. Vancomycin deserves consideration for inclusion in the prophylactic regimen (1) for prosthetic valve replacement and prosthetic vascular graft implantation, to reduce the risk of implant infection by methicillin-resistant coagulase-negative staphylococci and enterococci; (2) for any cardiovascular operation if the patient has recently received broad-spectrum antimicrobial therapy; and (3) for all cardiovascular operations in centers with a high prevalence of surgical infection with methicillin-resistant staphylococci or enterococci. Guidelines for dosing and administration of vancomycin for cardiovascular surgical prophylaxis are provided.

This article has been cited by other articles:

				T. Crawford, K. A. Rodvold, and J. S. Solomkin Vancomycin for Surgical Prophylaxis? Clinical Infectious Diseases, February 10, 2012; (2012) cis027v1. [Abstract] [Full Text] [PDF]

				Writing Committee Members, L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Thorac. Cardiovasc. Surg., January 1, 2012; 143(1): 4 - 34. [Full Text] [PDF]

				L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, A. M. Hutter Jr, et al. Special Article: 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Anesth. Analg., January 1, 2012; 114(1): 11 - 45. [Full Text] [PDF]

				L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, A. M. Hutter Jr, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 6, 2011; 58(24): 2584 - 2614. [Full Text] [PDF]

				L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, A. M. Hutter Jr, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 6, 2011; 58(24): e123 - e210. [Full Text] [PDF]

				Writing Committee Members, L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 6, 2011; 124(23): e652 - e735. [Full Text] [PDF]

				Writing Committee Members, L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 6, 2011; 124(23): 2610 - 2642. [Full Text] [PDF]

				R. O. Darouiche, M. D. Mansouri, and M. J. Schneidkraut Comparative Efficacies of Telavancin and Vancomycin in Preventing Device-Associated Colonization and Infection by Staphylococcus aureus in Rabbits Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2626 - 2628. [Abstract] [Full Text] [PDF]

				E. Tamayo, J. Gualis, S. Florez, J. Castrodeza, J. M. Eiros Bouza, and F. J. Alvarez Comparative study of single-dose and 24-hour multiple-dose antibiotic prophylaxis for cardiac surgery. J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1522 - 1527. [Abstract] [Full Text] [PDF]

				K. W. Garey, D. Lai, T. K. Dao-Tran, L. O. Gentry, L. Y. Hwang, and B. R. Davis Interrupted Time Series Analysis of Vancomycin Compared to Cefuroxime for Surgical Prophylaxis in Patients Undergoing Cardiac Surgery Antimicrob. Agents Chemother., February 1, 2008; 52(2): 446 - 451. [Abstract] [Full Text] [PDF]

				K. Dhadwal, S. Al-Ruzzeh, T. Athanasiou, M. Choudhury, P. Tekkis, P. Vuddamalay, H. Lyster, M. Amrani, and S. George Comparison of clinical and economic outcomes of two antibiotic prophylaxis regimens for sternal wound infection in high-risk patients following coronary artery bypass grafting surgery: a prospective randomised double-blind controlled trial Heart, September 1, 2007; 93(9): 1126 - 1133. [Abstract] [Full Text] [PDF]

				R. Engelman, D. Shahian, R. Shemin, T. S. Guy, D. Bratzler, F. Edwards, M. Jacobs, H. Fernando, and C. Bridges The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part II: Antibiotic Choice Ann. Thorac. Surg., April 1, 2007; 83(4): 1569 - 1576. [Full Text] [PDF]

				A. D. Caffarelli, J. P. Holden, E. J. Baron, H. J.M. Lemmens, H. D'Souza, V. Yau, C. Olcott IV, B. A. Reitz, D. C. Miller, and P. J.A. van der Starre Plasma cefazolin levels during cardiovascular surgery: Effects of cardiopulmonary bypass and profound hypothermic circulatory arrest J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1338 - 1343. [Abstract] [Full Text] [PDF]

				J. H. Khan and E. A. Davis Is Re-Dosing of Vancomycin Necessary? Ann. Thorac. Surg., February 1, 2006; 81(2): 789 - 789. [Full Text] [PDF]

				S. E. Baum and D. P. Dooley Preventing Methicillin-Resistant Staphylococcus aureus Infections in Cardiovascular Surgery Patients: Can We Do Any Better? Clinical Infectious Diseases, June 1, 2004; 38(11): 1561 - 1563. [Abstract] [Full Text] [PDF]

				M. K. Bolon, M. Morlote, S. G. Weber, B. Koplan, Y. Carmeli, and S. B. Wright Glycopeptides Are No More Effective than {beta}-Lactam Agents for Prevention of Surgical Site Infection after Cardiac Surgery: A Meta-analysis Clinical Infectious Diseases, May 15, 2004; 38(10): 1357 - 1363. [Abstract] [Full Text] [PDF]

				M.-R. Movahed, B. Kasravi, and C. S. Bryan Prophylactic Use of Vancomycin in Adult Cardiology and Cardiac Surgery Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 13 - 20. [Abstract] [PDF]

				A. A. Mangi, I. F. Palacios, and D. F. Torchiana Catheter pericardiocentesis for delayed tamponade after cardiac valve operation Ann. Thorac. Surg., May 1, 2002; 73(5): 1479 - 1483. [Abstract] [Full Text] [PDF]

				R. Finkelstein, G. Rabino, T. Mashiah, Y. Bar-El, Z. Adler, V. Kertzman, O. Cohen, and S. Milo Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections J. Thorac. Cardiovasc. Surg., February 1, 2002; 123(2): 326 - 332. [Abstract] [Full Text] [PDF]

				R. Saginur, D. Croteau, and M. G. Bergeron Comparative efficacy of teicoplanin and cefazolin for cardiac operation prophylaxis in 3027 patients J. Thorac. Cardiovasc. Surg., December 1, 2000; 120(6): 1120 - 1130. [Abstract] [Full Text] [PDF]

				S. Harbarth, M. H. Samore, D. Lichtenberg, and Y. Carmeli Prolonged Antibiotic Prophylaxis After Cardiovascular Surgery and Its Effect on Surgical Site Infections and Antimicrobial Resistance Circulation, June 27, 2000; 101(25): 2916 - 2921. [Abstract] [Full Text] [PDF]

				H. A. Kirst, D. G. Thompson, and T. I. Nicas Historical Yearly Usage of Vancomycin Antimicrob. Agents Chemother., May 1, 1998; 42(5): 1303 - 1304. [Full Text] [PDF]

				J. M. Rosenberg, J. A. Wahr, and K. A. Smith Effect of vancomycin infusion on cardiac function in patients scheduled for cardiac operation J. Thorac. Cardiovasc. Surg., March 1, 1995; 109(3): 561 - 564. [Abstract] [Full Text]